Metformin added to the adjuvant breast cancer therapy decreased metastasis and the inducible metastatic factors, HOMAIR and FBG, along with the reduced insulin levels. Increase in IGFBP-3 protective factor and decreased IGF-1 were reported. This evidence concerns the gene INS and breast carcinoma.